Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M60.7Revenue $M0.3Net Margin (%)-10,365.9Z-Score-17.7
Enterprise Value $M52.0EPS $-0.5Operating Margin %-10,444.3F-Score4
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-10,365.9Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %0Quick Ratio3.2Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-134.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-250.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M91.4ROI % (ttm)-121.7Gross Margin Increase y-yN

Gurus Latest Trades with CVM

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CVM is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CVM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KERSTEN GEERT RCEO 2014-10-13Buy14,999$0.77-12.99view
KERSTEN GEERT RCEO 2013-12-30Buy300,000$0.611.67view
KERSTEN GEERT RChief Executive 2013-10-09Buy8,400$0.79-15.19view
YOUNG PETER RDirector 2013-06-19Buy25,000$0.24179.17view
KERSTEN GEERT RChief Executive 2013-06-14Buy145,120$0.24179.17view
KERSTEN GEERT RCEO 2013-05-20Buy40,000$0.25168view
KERSTEN GEERT RCEO 2013-05-02Buy118,700$0.27148.15view
PRICHEP PATRICIA BSenior Vice President 2013-03-27Buy25,000$0.22204.55view
YOUNG PETER RDirector 2013-03-27Buy25,000$0.23191.3view
KERSTEN GEERT RCEO 2013-03-26Buy348,125$0.21219.05view

Press Releases about CVM :

    Quarterly/Annual Reports about CVM:

    News about CVM:

    Articles On GuruFocus.com
    Updated Coverage Report Focuses on CEL-SCI Corporation Jan 12 2015 
    Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 15 2014 
    CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
    CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
    CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
    CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
    CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 

    More From Other Websites
    CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into... Jan 26 2015
    Updated Coverage Report Focuses on CEL-SCI Corporation Jan 12 2015
    CEL-SCI to Present at Biotech Showcase 2015 Jan 09 2015
    NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv Jan 06 2015
    Date Set for Arbitration Trial Between CEL-SCI and Clinical Research Organization inVentiv Jan 06 2015
    NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and... Jan 05 2015
    CEL-SCI’s 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase III Head and Neck... Jan 05 2015
    CEL SCI CORP Financials Jan 01 2015
    NEW STORY CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments Dec 31 2014
    10-K for CEL-SCI Corp. Dec 25 2014
    CEL SCI CORP Files SEC form 10-K, Annual Report Dec 23 2014
    CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments Dec 23 2014
    NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with... Dec 08 2014
    CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7... Dec 08 2014
    NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases... Dec 02 2014
    CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight... Dec 02 2014
    NEW STORY CEL-SCI Enrolls 22 Patients during October in Its Phase III Immunotherapy Head and Neck... Nov 03 2014
    CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial Nov 03 2014
    NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million Nov 02 2014
    CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million Oct 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK